ESR1 and neoplasm: The mean survival rate was higher in the following patients: age younger than 40 years (298.43), ≥ high school education (307.65), married (293.16), premenopausal (298.04), stage I (343.6), grade II (218.4), negative ER (229.35), negative PR (228.6), positive Her2 receptor (159.4), negative P53 receptor (181.6), pathology reports other than invasive ductal carcinoma (315.4), no lymph node involvement (300.5), tumor size < 2 cm (277.75), MRM surgery (275.5), and patients not receiving chemotherapy (328.7), radiotherapy (312.9), or hormone therapy (282.3) (Table 1).